BML Capital Management, LLC Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0001616824
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2023 · 26 positions · Total reported value $108.90M · Top-10 concentration 89.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 38.1% · 3 new · 4 cut · 1 exited
Active Share (vs S&P 500): 99.2% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): +2.1% · vs SPY -0.0% · Prev Value $176.05M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -15.2% · vs SPY -17.3% · Latest Value $187.62M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2023 13F filing, BML Capital Management, LLC disclosed 26 equity positions with a combined reported value of $108.90M. The filing implies a focused portfolio: its ten largest positions account for 89.6% of reported value. HoldingsHub classifies the profile as Small / Focused / High Turnover.
The largest disclosed positions as of Q3 2023 were SGOV ($27.18M), BIL ($18.36M), AVIR ($14.40M). By sector, the heaviest allocations are Health Care 25.1%, Industrials 2.0%.
Versus the prior quarter, BML Capital Management, LLC opened 3 new positions, trimmed 4 and fully exited 1, a turnover rate of 38.1% of positions.
The largest new positions opened in Q3 2023 were SGOV ($27.18M), BIL ($18.36M), AVIR ($14.40M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2023)
- SGOV ISHARES TR · $27.18M
- BIL State Street SPDR Portfolio · $18.36M
- AVIR ATEA PHARMACEUTICALS INC · $14.40M
- CYTT CYTEIR THERAPEUTICS INC · $9.23M
- AVRO AVROBIO INC · $6.16M
- ADVM ADVERUM BIOTECHNOLOGIES INC · $5.87M
- TALS TALARIS THERAPEUTICS INC · $5.62M
- CLYM CLIMB BIO INC · $5.10M
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest BML Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
BML Capital Management, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 18 positions worth $176.05M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 18 positions · $176.05M reported value (Q2 2026)
- Top 10 holdings = 93.3% of reported value
- Largest position: ACRS (ACLARIS THERAPEUTICS INC) at 36.0%
- Average position size: $9.78M
Sector Tilt
- Health Care 80.1%
- Consumer Discretionary 13.3%
- Consumer Staples 6.2%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 3 new, 4 added, 3 reduced, 1 exited
- 8 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
270.00K | $27.18M | 24.96% | New | |
| 2 |
|
200.00K | $18.36M | 16.86% | New | |
| 3 |
|
4.80M | $14.40M | 13.22% | New | |
| 4 |
|
3.25M | $9.23M | 8.48% | New | |
| 5 |
|
4.00M | $6.16M | 5.66% | New | |
| 6 |
|
3.92M | $5.87M | 5.39% | New | |
| 7 |
|
2.00M | $5.62M | 5.16% | New | |
| 8 |
|
1.94M | $5.10M | 4.68% | New | |
| 9 |
|
1.70M | $3.44M | 3.16% | New | |
| 10 |
|
220.41K | $2.23M | 2.04% | New | |
| 11 |
|
781.29K | $2.04M | 1.87% | New | |
| 12 |
|
706.93K | $1.42M | 1.30% | New | |
| 13 |
|
2.06M | $1.35M | 1.24% | New | |
| 14 |
|
1.76M | $1.17M | 1.07% | New | |
| 15 |
|
272.50K | $844.75K | 0.78% | New | |
| 16 |
|
50.00K | $683.00K | 0.63% | New | |
| 17 |
|
499.96K | $594.95K | 0.55% | New | |
| 18 |
|
150.00K | $582.75K | 0.54% | New | |
| 19 |
|
100.00K | $524.00K | 0.48% | New | |
| 20 |
|
243.84K | $521.82K | 0.48% | New | |
| 21 |
|
108 | $443.88K | 0.41% | New | |
| 22 |
|
306.46K | $395.34K | 0.36% | New | |
| 23 |
|
98.66K | $389.72K | 0.36% | New | |
| 24 |
|
88.78K | $236.11K | 0.22% | New | |
| 25 |
|
72.93K | $62.85K | 0.06% | New | |
| 26 |
|
89.27K | $43.74K | 0.04% | New | |
FAQ
What did BML Capital Management, LLC buy in 2023-Q3?
In its 2023-Q3 13F filing, BML Capital Management, LLC reported 26 equity positions worth $108.90M in aggregate; its largest disclosed positions were SGOV ($27.18M), BIL ($18.36M), AVIR ($14.40M).
How large is BML Capital Management, LLC's portfolio?
BML Capital Management, LLC reported $108.90M of long equity holdings across 26 positions as of 2023-Q3. Top-10 holdings account for 89.6% of reported value.
What is BML Capital Management, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.